Bespoken Nanoceria: An Effective Treatment in Experimental Hepatocellular Carcinoma.

ABSTRACT:

Background and aims

Despite the availability of new-generation drugs, hepatocellular carcinoma (HCC) is still the third most frequent cause of cancer-related deaths worldwide. Cerium oxide nanoparticles (CeO₂ NPs) have emerged as an antioxidant agent in experimental liver disease because of their antioxidant, anti-inflammatory, and antisteatotic properties. In the present study, we aimed to elucidate the potential of CeO₂ NPs as therapeutic agents in HCC.

Approach and results

HCC was induced in 110 Wistar rats by intraperitoneal administration of diethylnitrosamine for 16 weeks. Animals were treated with vehicle or CeO₂ NPs at weeks 16 and 17. At the eighteenth week, nanoceria biodistribution was assessed by mass spectrometry (MS). The effect

SUBMITTER: Fernandez-Varo G 

PROVIDER: S-EPMC7702051 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature